IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting
29 9월 2023 - 9:00PM
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today announced two poster presentations reporting
positive data at the Society for Immunotherapy of Cancer’s (SITC)
38th Annual Meeting, taking place November 1-5, 2023, in San Diego,
CA. The presentations will showcase biological correlative data
from the ongoing Phase 1 clinical trial of INB-200, targeting newly
diagnosed glioblastoma multiforme (GBM) and pre-clinical insights
on IN8bio’s induced pluripotent stem cell (iPSC) gamma-delta T cell
platform.
Details of the presentations at SITC 2023 are as
follows:
Title: INB-200: Phase I study of gene modified
autologous gamma-delta (γδ) T cells in newly diagnosed glioblastoma
(GBM) patients receiving maintenance temozolomide (TMZ):
immunobiologic correlative dataAbstract #:
637Location: Exhibit Halls A and B1 – San Diego
Convention CenterData and Time: Friday November 3,
2023, 9:00 AM – 8:30 PM PDT
Title: The Development of “Off-the-Shelf”
manufacturing strategies of iPSC-based Gamma-Delta T
CellsAbstract #: 418Location:
Exhibit Halls A and B1 – San Diego Convention CenterData
and Time: Saturday November 4, 2023, 9:00 AM – 8:30 PM
PDT
About the INB-200 Phase 1 TrialINB-200 is a
genetically modified autologous drug resistant immunotherapy (DRI)
product candidate for the treatment of solid tumors. This novel
platform utilizes genetic engineering to generate chemotherapy
resistant gamma delta T cells which can be administered
concurrently with standard-of-care treatment in solid tumors. This
is a powerful, synergistic treatment approach enabling gamma-delta
T cells to persist in the presence of chemotherapy, and maintain
their natural ability to recognize, engage and kill cancer
cells.
INB-200 is the first genetically engineered gamma-delta T cell
therapy to be administered to patients with solid tumors and our
initial indication is in GBM.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of gamma-delta T
cell product candidates for solid and liquid tumors. Gamma-delta T
cells are a specialized population of T cells that possess unique
properties, including the ability to differentiate between healthy
and diseased tissue. IN8bio’s DeltEx platform employs allogeneic,
autologous, iPSC and genetically modified approaches to develop
cell therapies designed to effectively identify and eradicate tumor
cells.
IN8bio is currently conducting two investigator-initiated Phase
1 clinical trials for its lead gamma-delta T cell product
candidates: INB-200 for the treatment of newly diagnosed
glioblastoma and INB-100 for the treatment of patients with
hematologic malignancies undergoing haploidentical hematopoietic
stem cell transplantation. IN8bio is initiating INB-400, a
company-sponsored multi-center Phase 2 clinical trial in newly
diagnosed glioblastoma, which received IND clearance in late 2022.
IN8bio also has a broad portfolio of preclinical programs focused
on addressing other hematological and solid tumor cancers. For more
information about IN8bio and its programs, please visit
www.IN8bio.com.
Company Contact:IN8bio, Inc.Patrick McCall+ 1
646.600.6GDT (6438)info@IN8bio.com
Investors & Media Contact: Argot
PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
IN8bio (NASDAQ:INAB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024